Mesenchymal phenotype of CTC-enriched blood fraction and lymph node metastasis formation potential

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Markiewicz, Aleksandra ^a,b   Ksia̧zkiewicz, Magdalena ^a   Wełnicka Jaśkiewicz, Marzena ^a   Seroczyńska, Barbara ^a   Skokowski, Jarosław ^a   Szade, Jolanta ^a   Zaczek, Anna J ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CYTOKERATIN 19; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MAMMAGLOBIN A; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TUMOR MARKER;

ARTICLE; BLOOD; BREAST CANCER; CANCER PATIENT; CELL ISOLATION; CIRCULATING TUMOR CELL; CONTROLLED STUDY; CORRELATION ANALYSIS; CXCR4 GENE; DENSITY GRADIENT CENTRIFUGATION; FEMALE; FRACTIONATION; GENE; GENE EXPRESSION; GENETIC MARKER; HER2 GENE; HUMAN; HUMAN CELL; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MGB1 GENE; PHENOTYPE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SLUG GENE; SNAIL GENE; TWIST1 GENE; UPAR GENE; VIM GENE; ADULT; AGED; BREAST TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR EMBOLISM; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84899441293     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093901     Document Type: Article

References (62)

1. Ashworth T (1869) A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J 14: 146-147.
2. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, et al. (2013) Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339: 580-584.
3. Stoecklein NH, Klein CA (2010) Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. International Journal of Cancer 126: 589-598.
4. Banys M, Muller V, Melcher C, Aktas B, Kasimir-Bauer S, et al. (2013) Circulating tumor cells in breast cancer. Clinica Chimica Acta 423: 39-45.
5. Chaffer CL, Weinberg RA (2011) A Perspective on Cancer Cell Metastasis. Science 331: 1559-1564.
6. Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, et al. (2012) Circulating tumour cells in non-metastatic breast cancer: a prospective study. The Lancet Oncology 13: 688-695.
7. Bidard FC, Mathiot C, Delaloge S, Brain E, Giachetti S, et al. (2010) Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Annals of Oncology 21: 729-733.
8. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, et al. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New England Journal of Medicine 351: 781-791. (Pubitemid 39095313)
9. Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, et al. (2011) Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Research 13.
10. Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, et al. (2009) Cytokeratin-19 mRNA-Positive Circulating Tumor Cells After Adjuvant Chemotherapy in Patients With Early Breast Cancer. Journal of Clinical Oncology 27: 2177-2184.
11. Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis C, et al. (2002) Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. Journal of Clinical Oncology 20: 3404-3412.
12. Zhao S, Liu Y, Zhang Q, Li H, Zhang M, et al. (2011) The prognostic role of circulating tumor cells (CTCs) detected by RT-PCR in breast cancer: a metaanalysis of published literature. Breast Cancer Research and Treatment 130: 809-816.
13. Strati A, Kasimir-Bauer S, Markou A, Parisi C, Lianidou ES (2013) Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer. Breast Cancer Research 15: R20.
14. Andergassen U, Kolbl AC, Hutter S, Friese K, Jeschke U (2013) Detection of Circulating Tumour Cells from Blood of Breast Cancer Patients via RT-qPCR. Cancers 5: 1212-1220.
15. Daskalaki A, Agelaki S, Perraki M, Apostolaki S, Xenidis N, et al. (2009) Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. Br J Cancer 101: 589-597.
16. Pierga JY, Bonneton C, Vincent-Salomon A, de Cremoux P, Nos C, et al. (2004) Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clinical Cancer Research 10: 1392-1400. (Pubitemid 38365234)
17. Tamaki Y, Akiyama F, Iwase T, Kaneko T, Tsuda H, et al. (2009) Molecular detection of lymph node metastases in breast cancer patients: results of a multicenter trial using the one-step nucleic acid amplification assay. Clinical Cancer Research 15: 2879-2884.
18. Inokuchi M, Ninomiya I, Tsugawa K, Terada I, Miwa K (2003) Quantitative evaluation of metastases in axillary lymph nodes of breast cancer. Br J Cancer 89: 1750-1756. (Pubitemid 37464150)
19. Konigsberg R, Obermayr E, Bises G, Pfeiler G, Gneist M, et al. (2011) Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta oncologica 50: 700-710.
20. Raimondi C, Gradilone A, Naso G, Vincenzi B, Petracca A, et al. (2011) Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Research and Treatment 130: 449-455.
21. Bonnomet A, Brysse A, Tachsidis A, Waltham M, Thompson EW, et al. (2010) Epithelial-to-mesenchymal transitions and circulating tumor cells. J Mammary Gland Biol Neoplasia 15: 261-273.
22. Mego M, Mani SA, Lee BN, Li C, Evans KW, et al. (2012) Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. International Journal of Cancer 130: 808-816.
23. Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, et al. (2008) Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clinical Cancer Research 14: 2593-2600.
24. Markou A, Strati A, Malamos N, Georgoulias V, Lianidou ES (2011) Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay. Clin Chem 57: 421-430.
25. Reinholz MM, Kitzmann KA, Tenner K, Hillman D, Dueck AC, et al. Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437. Clinical Cancer Research 17: 7183-7193.
26. Corradini P, Voena C, Astolfi M, Delloro S, Pilotti S, et al. (2001) Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer. Annals of Oncology 12: 1693-1698. (Pubitemid 34105658)
27. Bossolasco P, Ricci C, Farina G, Soligo D, Pedretti D, et al. (2002) Detection of micrometastatic cells in breast cancer by RT-pCR for the mammaglobin gene. Cancer Detect Prev 26: 60-63. (Pubitemid 36087183)
28. Marchetti A, Buttitta F, Bertacca G, Zavaglia K, Bevilacqua G, et al. (2001) mRNA markers of breast cancer nodal metastases: comparison between mammaglobin and carcinoembryonic antigen in 248 patients. J Pathol 195: 186-190. (Pubitemid 32899027)
29. Leygue E, Snell L, Dotzlaw H, Hole K, Troup S, et al. (1999) Mammaglobin, a potential marker of breast cancer nodal metastasis. J Pathol 189: 28-33. (Pubitemid 29406815)
30. Kataoka A, Mori M, Sadanaga N, Ueo H, Tsuji K, et al. (2000) RT-PCR detection of breast cancer cells in sentinel lymph modes. Int J Oncol 16: 1147-1152.
31. Vazquez-Martin A, Oliveras-Ferraros C, Cufi S, Del Barco S, Martin-Castillo B, et al. (2010) Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell cycle 9: 3807-3814.
32. Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, et al. (2007) Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Research 67: 1979-1987. (Pubitemid 46424214)
33. Theys J, Jutten B, Habets R, Paesmans K, Groot AJ, et al. (2011) E-Cadherin loss associated with EMT promotes radioresistance in human tumor cells. Radiotherapy and oncology 99: 392-397.
34. Andreasen PA, Kjoller L, Christensen L, Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. International Journal of Cancer 72: 1-22. (Pubitemid 27314632)
35. Aguirre Ghiso JA, Kovalski K, Ossowski L (1999) Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 147: 89-104.
36. Meng S, Tripathy D, Shete S, Ashfaq R, Saboorian H, et al. (2006) uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proceedings of the National Academy of Sciences of the United States of America 103: 17361-17365. (Pubitemid 44788974)
37. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, et al. (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537-549. (Pubitemid 36808649)
38. Muller A, Homey B, Soto H, Ge N, Catron D, et al. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56. (Pubitemid 32225831)
39. Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, et al. (2004) Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6: 459-469. (Pubitemid 39469982)
40. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ (2012) WHO Classification of Tumours of the Breast: International Agency for Research on Cancer.
41. Zaczek AJ, Markiewicz A, Seroczynska B, Skokowski J, Jaskiewicz J, et al. (2012) Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancer. The oncologist 17: 1246-1255.
42. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Research and Treatment 100: 229-235. (Pubitemid 44631925)
43. Markiewicz A, Ksiazkiewicz M, Seroczynska B, Skokowski J, Szade J, et al. (2013) Heterogeneity of mesenchymal markers expression-molecular profiles of cancer cells disseminated by lymphatic and hematogenous routes in breast cancer. Cancers (Basel) 5: 1485-1503.
44. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J (2007) qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol 8: R19.
45. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, et al. (2006) GenePattern 2.0. Nature Genetics 38: 500-501.
46. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, et al. (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13: 58-68. (Pubitemid 350309740)
47. Molloy TJ, Devriese LA, Helgason HH, Bosma AJ, Hauptmann M, et al. (2011) A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer. British Journal of Cancer 104: 1913-1919.
48. Wulfing P, Borchard J, Buerger H, Heidl S, Zanker KS, et al. (2006) HER2- positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clinical Cancer Research 12: 1715-1720.
49. Rack BK, Schindlbeck C, Andergassen U, Schneeweiss A, Zwingers T, et al. (2010) Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: The SUCCESS trial. Journal of Clinical Oncology.
50. Lasa A, Garcia A, Alonso C, Millet P, Cornet M, et al. (2013) Molecular detection of peripheral blood breast cancer mRNA transcripts as a surrogate biomarker for circulating tumor cells. PLoS One 8: e74079.
51. Kundu GC, Mantile G, Miele L, Cordella-Miele E, Mukherjee AB (1996) Recombinant human uteroglobin suppresses cellular invasiveness via a novel class of high-affinity cell surface binding site. Proceedings of the National Academy of Sciences of the United States of America 93: 2915-2919. (Pubitemid 26116247)
52. Heyns W, Bossyns D (1983) A comparative study of estramustine and pregnenolone binding to prostatic binding protein: evidence for subunit cooperativity. J Steroid Biochem 19: 1689-1694. (Pubitemid 14191542)
53. Benoy IH, Elst H, Philips M, Wuyts H, Van Dam P, et al. (2006) Real-time RTPCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. British Journal of Cancer 94: 672-680. (Pubitemid 43361898)
54. Raynor MP, Stephenson SA, Pittman KB, Walsh DC, Henderson MA, et al. (2009) Identification of circulating tumour cells in early stage breast cancer patients using multi marker immunobead RT-PCR. Journal of hematology & oncology 2: 24.
55. Chen Y, Zou TN, Wu ZP, Zhou YC, Gu YL, et al. (2010) Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer. Int J Biol Markers 25: 59-68.
56. Pecot CV, Bischoff FZ, Mayer JA, Wong KL, Pham T, et al. (2011) A Novel Platform for Detection of CK+ and CK2 CTCs. Cancer Discovery 1: 580-586.
57. Andergassen U, Hofmann S, Kolbl AC, Schindlbeck C, Neugebauer J, et al. (2013) Detection of Tumor Cell-Specific mRNA in the Peripheral Blood of Patients with Breast Cancer& #8212;Evaluation of Several Markers with Real-Time Reverse Transcription-PCR. Int J Mol Sci 14: 1093-1104.
58. Zhao S, Yang H, Zhang M, Zhang D, Liu Y, et al. (2013) Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients. Cell biochemistry and biophysics 65: 263-273.
59. Hemsen A, Riethdorf L, Brunner N, Berger J, Ebel S, et al. (2003) Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells. International Journal of Cancer 107: 903-909. (Pubitemid 37429831)
60. Bonnomet A, Syne L, Brysse A, Feyereisen E, Thompson EW, et al. (2012) A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer. Oncogene 31: 3741-3753.
61. Giordano A, Gao H, Anfossi S, Cohen E, Mego M, et al. (2012) Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Molecular cancer therapeutics 11: 2526-2534.
62. Alpaugh ML, Tomlinson JS, Kasraeian S, Barsky SH (2002) Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma. Oncogene 21: 3631-3643. (Pubitemid 34587695)